Floatz logo

Tas-102

Recurrent Pancreatic Cancer

The University of Hong KongunclassifiedPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
azd6244
National Cancer Institute (NCI)
Phase 2BB
su011248
OHSU Knight Cancer Institute
Phase 3BB
Dasatinib
OHSU Knight Cancer Institute
Phase 2BB
Sorafenib
Roswell Park Cancer Institute
Phase 2BB

View all 31 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →